Search

Your search keyword '"Huang, Xiao-Wu"' showing total 254 results
Start Over Author "Huang, Xiao-Wu"
254 results on '"Huang, Xiao-Wu"'

2. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Author

Shi, Guo-Ming, Huang, Xiao-Yong, Wu, Dong, Sun, Hui-Chuan, Liang, Fei, Ji, Yuan, Chen, Yi, Yang, Guo-Huan, Lu, Jia-Cheng, Meng, Xian-Long, Wang, Xin-Ying, Sun, Lei, Ge, Ning-Ling, Huang, Xiao-Wu, Qiu, Shuang-Jian, Yang, Xin-Rong, Gao, Qiang, He, Yi-Feng, Xu, Yang, Sun, Jian, Ren, Zheng-Gang, Fan, Jia, and Zhou, Jian

Published
2023
Full Text
View/download PDF

5. ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).

Author

Fan, Jia, primary, Zhou, Jian, additional, Shi, Guoming, additional, Huang, Xiaoyong, additional, Ma, Liang, additional, Wang, Jun-Ye, additional, Gao, Qiang, additional, Qiu, Shuangjian, additional, Sun, Huichuan, additional, Shi, Yinghong, additional, Huang, Xiao-Wu, additional, Wang, Xiaoying, additional, Yi, Yong, additional, Zhu, Xiaodong, additional, Huang, Cheng, additional, Ding, Zhenbin, additional, Chen, Yi, additional, He, Yi-Feng, additional, Shen, Yinghao, additional, and Sun, Qiman, additional

Published
2024
Full Text
View/download PDF

17. Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis

Author

Song, Dan-Jun, primary, Zhu, Kai, additional, Tan, Jin-peng, additional, Cai, Jia-Bin, additional, Lv, Min-Zhi, additional, Hu, Jie, additional, Ding, Zhen-Bin, additional, Shi, Guo-Ming, additional, Ren, Ning, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Sun, Hui-Chuan, additional, Gao, Qiang, additional, Zhou, Jian, additional, Fan, Jia, additional, and Wang, Xiao-Ying, additional

Published
2022
Full Text
View/download PDF

18. Metagenomic Next-Generation Sequencing Versus Traditional Laboratory Methods for the Diagnosis and Treatment of Infection in Liver Transplantation

Author

Huang, Jun-Feng, primary, Miao, Qing, additional, Cheng, Jian-Wen, additional, Huang, Ao, additional, Guo, De-Zhen, additional, Wang, Ting, additional, Yang, Liu-Xiao, additional, Zhu, Du-Ming, additional, Cao, Ya, additional, Huang, Xiao-Wu, additional, Fan, Jia, additional, Zhou, Jian, additional, and Yang, Xin-Rong, additional

Published
2022
Full Text
View/download PDF

19. Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study.

Author

Huang, Ao, primary, Guo, De-Zhen, additional, Zhang, Xuan, additional, Sun, Ying, additional, Zhang, Xin, additional, Fu, XiuTao, additional, Wang, Yupeng, additional, Yang, Guo-Huan, additional, Sun, Qiman, additional, He, Yifeng, additional, Song, Kang, additional, Huang, Xiao-Wu, additional, Liu, Wei-Ren, additional, Ding, Zhen-Bing, additional, Shi, Ying-Hong, additional, Fan, Jia, additional, and Zhou, Jian, additional

Published
2022
Full Text
View/download PDF

20. Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.

Author

Zhou, Jian, primary, Sun, Hui-Chuan, additional, Huang, Zhi-Yong, additional, Liu, Lianxin, additional, Wen, Tianfu, additional, Zhu, Xiao-Dong, additional, SHI, Yinghong, additional, Gao, Qiang, additional, Qiu, Shuang-Jian, additional, Ding, Zhenbin, additional, Wang, Zheng, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Huang, Cheng, additional, Peng, Yuan-Fei, additional, Shi, Guoming, additional, Wang, Xiao-Ying, additional, and Fan, Jia, additional

Published
2022
Full Text
View/download PDF

22. Identification of competing endogenous RNA network in laryngeal squamous cell carcinoma.

Author

Cui, Xiao‐Feng, Zhang, Si‐Lin, Wang, Wei‐Ping, Huang, Xiao‐Wu, and Chen, Xiang‐Jun

Subjects
HEAD & neck cancer diagnosis, REVERSE transcriptase polymerase chain reaction, HEAD & neck cancer, LARYNGEAL tumors, GENE expression, MATHEMATICAL variables, CANCER patients, MESSENGER RNA, RESEARCH funding, SQUAMOUS cell carcinoma
Abstract

Objective: This study was conducted to investigate key long noncoding RNAs (lncRNAs) involved in competitive endogenous RNA (ceRNA) network associated with laryngeal squamous cell carcinoma (LSCC). Materials and Methods: Three mRNA datasets, two miRNA datasets, and one lncRNA dataset of LSCC were downloaded from GEO database. Following the identification of differentially expressed mRNAs (DEmRNAs), (microRNAs) miRNAs (DEmiRNAs), and lncRNAs (DElncRNAs) in LSCC compared with adjacent tissues, functional enrichment of DEmRNAs was performed. Then, construction of the ceRNA (DElncRNA‐DEmiRNA‐DEmRNA) regulatory network and functional analyses of all DEmRNAs in ceRNA regulatory network were conducted. Quantitative real‐time polymerase chain reactions (qRT‐PCR) were used to detect the expression levels of selected DEmRNAs, DEmiRNAs, and DElncRNAs. Results: A total of 3449 DEmRNAs, 40 DEmiRNAs, and 100 DElncRNAs were identified in LSCC. The ceRNA networks, which contained 132 DElncRNA‐DEmiRNA pairs and 287 DEmiRNA‐DEmRNA pairs, involving 44 lncRNAs, 3 miRNAs, and 271 mRNAs, were obtained. DEmRNAs in ceRNA regulatory networks were significantly enriched in pathways in cancer, prostate cancer, and aldosterone‐regulated sodium reabsorption. Except for HCG22 and hsa‐miR‐1246, expressions of the others in the qRT‐PCR results played the same pattern with that in our integrated analysis, generally. Conclusions: We concluded that HCG22/EGOT‐hsa‐miR‐1275‐FAM107A and HCG22/EGOT‐hsa‐miR‐1246‐Glycerol‐3‐phosphate dehydrogenase 1 like interaction pairs may play a central role in LSCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Corrigendum to ‘Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence’ [J Hepatol 71 (2019) 1152-63]

Author

Zhou, Shao-Lai, primary, Zhou, Zheng-Jun, additional, Hu, Zhi-Qiang, additional, Song, Cheng-Li, additional, Luo, Yi-Jie, additional, Luo, Chu-Bin, additional, Xin, Hao-Yang, additional, Yang, Xin-Rong, additional, Shi, Ying-Hong, additional, Wang, Zheng, additional, Huang, Xiao-Wu, additional, Cao, Ya, additional, Fan, Jia, additional, and Zhou, Jian, additional

Published
2022
Full Text
View/download PDF

33. TM2D1 contributes the epithelial-mesenchymal transition of hepatocellular carcinoma via modulating AKT/β-catenin axis

Author

Hu, Jin-Wu, Yin, Yue, Gao, Yang, Nie, Yan-Yan, Fu, Pei-Yao, Cai, Jia-Bin, Zhu, Kai, Huang, Cheng, Huang, Xiao-Wu, Yang, Xin-Rong, Cao, Ya, Qiu, Shuang-Jian, Fan, Jia, and Zhou, Jian

Subjects
Original Article
Abstract

Various epidemiology studies showed the correlation between Alzheimer's disease (AD) and low incidence of cancer. However, the etiology underlying etiology of AD-related carcinogenesis remains largely elusive. Our study focused on characterizing the role of TM2D1 (TM2 domain containing 1) in hepatocellular carcinoma. TM2D1 is also known as β-amyloid peptide binding protein and is critical to the pathogenesis of AD. We found that TM2D1 is increasingly expressed in HCC tumors relative to the peritumoral tissues of the matched tumors and high TM2D1 expression predicts unfavorable clinical outcomes. TM2D1 overexpression induced HCC cell proliferation, migration and invasion, which was related to the epithelial-mesenchymal transition (EMT) observed in these cells. Conversely, TM2D1 depletion led to opposite phenotype in HCC. Mechanistically, we found that TM2D1 promoted Akt and β-catenin hyper-activation, which corresponded with molecular marker change in EMT signaling pathway. Taken together, our results indicated that TM2D1 played an important role in the EMT process in HCC cells by activating AKT and β-catenin signaling and may become a promising therapeutic target in HCC.

Published
2021

36. Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Yang, Guo-Huan, additional, Ji, Yuan, additional, Chen, Yi, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Ge, Ning-Ling, additional, Sun, Hui-Chuan, additional, Huang, Xiao-Wu, additional, Qiu, Shuang-Jian, additional, He, Yi-Feng, additional, Yang, Xin-Rong, additional, Xu, Yang, additional, Gao, Qiang, additional, and Sun, Jian, additional

Published
2021
Full Text
View/download PDF

37. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Yang, Guo-Huan, additional, Lu, Jia-Cheng, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Xiao-Ying, additional

Published
2021
Full Text
View/download PDF

38. Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.

Author

Shi, Guo-Ming, primary, Jian, Zhou, additional, Fan, Jia, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Yang, Guo-Huan, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Zheng, additional

Published
2021
Full Text
View/download PDF

47. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF‐kB signaling pathways synergistically

Author

Zhang, Xin, primary, Hu, Bo, additional, Sun, Yun‐Fan, additional, Huang, Xiao‐Wu, additional, Cheng, Jian‐Wen, additional, Huang, Ao, additional, Zeng, Hai‐Ying, additional, Qiu, Shuang‐Jian, additional, Cao, Ya, additional, Fan, Jia, additional, Zhou, Jian, additional, and Yang, Xin‐Rong, additional

Published
2021
Full Text
View/download PDF

48. Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation

Author

Huang, Ao, primary, Guo, De-Zhen, additional, Wang, Yu-Peng, additional, Yang, Guo-Huan, additional, Sun, Qi-Man, additional, Zhang, Xin, additional, He, Yi-Feng, additional, Song, Kang, additional, Huang, Xiao-Wu, additional, Yang, Xin-Rong, additional, Fan, Jia, additional, Zhou, Jian, additional, and Hu, Jie, additional

Published
2021
Full Text
View/download PDF

50. Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti–Programmed Death 1 Immunotherapy for Recurrent Liver Tumors

Author

Shi, Guo‐Ming, primary, Wang, Jiping, additional, Huang, Xiao‐Wu, additional, Huang, Xiao‐Yong, additional, He, Yi‐Feng, additional, Ji, Yuan, additional, Chen, Yi, additional, Wu, Dong, additional, Lu, Jia‐Cheng, additional, Sun, Qi‐Man, additional, Liu, Wei‐Ren, additional, Wang, Ting, additional, Yang, Liu‐Xiao, additional, Hou, Ying‐Yong, additional, Shi, Ying‐Hong, additional, Sun, Jian, additional, Xiao, Yong‐Sheng, additional, Wang, Zheng, additional, Fan, Jia, additional, Bertagnolli, Monica M., additional, and Zhou, Jian, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results